Tears contain the complement regulator CD59 as well as decay-accelerating factor (DAF)

被引:26
作者
Cocuzzi, E
Szczotka, LB
Brodbeck, WG
Bardenstein, DS
Wei, T
Medof, ME
机构
[1] Case Western Reserve Univ, Sch Med, Inst Pathol, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Ctr Vis Res, Cleveland, OH 44106 USA
关键词
tears; complement; decay-accelerating factor; membrane cofactor protein; CD59;
D O I
10.1046/j.1365-2249.2001.01408.x
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Previous studies have shown that DAF (or CD55), a cell surface inhibitor of autologous C3 activation, is present in tears and that > 90% of the C3 convertase regulatory activity in tear fluid resides in this protein (Lass JH et al., Invest Ophth Vis Sci 1990; 31:1136-48). This study investigated whether (i) the membrane cofactor protein (MCP or CD46), an additional factor that regulates C3 activation, and (ii) the membrane inhibitor of reactive lysis (MIRL or CD59), a cell surface regulator that acts to prevent formation of the membrane attack complex, are also present in tears, and if so, are functional. Two-site immunoradiometric assays showed that MCP is present in tears at low levels (42 + 8 ng/ml, n = 8) while CD59 is present at levels (222 + 78 ng/ml, n = 14) comparable to those of DAF (325 + 289 ng/ml, n = 12). The concentrations of CD59 (i) were increased two-fold or more in closed eye tears, and (ii) were decreased in reflex tears. Western blotting showed that CD59 protein in tears migrates with an apparent mol. wt similar to membrane CD59 protein. Phenyl-Sepharose adsorption and Triton X-114 partitioning of tear CD59 as well as of tear DAF however, showed that both proteins are devoid of GPI anchors. Assays using cobra venom factor-activated human serum and guinea pig erythrocytes showed that CD59 is functionally active in inhibiting autologous C5b-9-mediated lysis and, under constitutive conditions, accounts for > 85% of the C9 inhibitory activity in tear fluid.
引用
收藏
页码:188 / 195
页数:8
相关论文
共 34 条
[1]  
ABBAS AK, 1997, CELLULAR MOL IMMUNOL, P313
[2]  
ADAMS EM, 1991, J IMMUNOL, V147, P3005
[3]   A HUMAN CELL-SURFACE ANTIGEN DEFINED BY A MONOCLONAL-ANTIBODY AND CONTROLLED BY A GENE ON HUMAN CHROMOSOME-1 [J].
ANDREWS, PW ;
KNOWLES, BB ;
PARKAR, M ;
PYM, B ;
STANLEY, K ;
GOODFELLOW, PN .
ANNALS OF HUMAN GENETICS, 1985, 49 (JAN) :31-39
[4]  
Bardenstein DS, 1999, INVEST OPHTH VIS SCI, V40, P519
[5]   LOCALIZATION OF THE COMPLEMENT MEMBRANE ATTACK COMPLEX INHIBITOR (CD59) IN HUMAN CONJUNCTIVA AND LACRIMAL GLAND [J].
BARDENSTEIN, DS ;
DIETZ, Y ;
LASS, JH ;
MEDOF, ME .
CURRENT EYE RESEARCH, 1994, 13 (12) :851-855
[6]  
BORA NS, 1993, INVEST OPHTH VIS SCI, V34, P3579
[7]  
CHO SW, 1991, CLIN EXP IMMUNOL, V83, P257
[8]   MEMBRANE DEFENSE AGAINST COMPLEMENT LYSIS - THE STRUCTURE AND BIOLOGICAL PROPERTIES OF CD59 [J].
DAVIES, A ;
LACHMANN, PJ .
IMMUNOLOGIC RESEARCH, 1993, 12 (03) :258-275
[9]   CD59, AN LY-6-LIKE PROTEIN EXPRESSED IN HUMAN LYMPHOID-CELLS, REGULATES THE ACTION OF THE COMPLEMENT MEMBRANE ATTACK COMPLEX ON HOMOLOGOUS CELLS [J].
DAVIES, A ;
SIMMONS, DL ;
HALE, G ;
HARRISON, RA ;
TIGHE, H ;
LACHMANN, PJ ;
WALDMANN, H .
JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (03) :637-654
[10]  
Ember J., 1998, The Human Complement System in Health and Disease, P241